Finnrick published an article titled “Why Endotoxin Testing Matters for Peptides,” summarizing endotoxin results from 140 peptide samples tested through January 2026.
According to the published data:
- Nearly 63% had no endotoxin detected.
- Approximately 29% produced an assay response below the test’s limit of quantification.
- Nearly 8% contained a quantifiable amount of endotoxin.
Put another way, approximately 92% of the samples contained no quantifiable endotoxin.
That is an important distinction when interpreting the results.
Quantifiable Does Not Automatically Mean Above Specification
A laboratory result can be detectable or quantifiable without necessarily exceeding an established quality-control threshold.
Finnrick describes several result ranges, including:
- Less than 5 EU per vial: trace-level findings
- 5–40 EU per vial: detectable contamination
- More than 40 EU per vial: above Finnrick’s stated quality-control threshold
- Higher result levels: evaluated separately according to the applicable analytical standard and study requirements
Finnrick identifies 40 EU per vial as its quality-control threshold. That threshold should not be confused with the analytical method’s limit of detection or limit of quantification.
These terms describe different concepts:
- Detected means the analytical method produced a response consistent with the presence of endotoxin.
- Quantified means the laboratory was able to calculate an amount with sufficient analytical confidence.
- Above specification means the measured result exceeded a defined acceptance criterion.
- Research suitability depends on the analytical requirements, study design, material specifications, handling conditions, and laboratory standards being applied.
A quantifiable result therefore does not automatically establish that a sample exceeded Finnrick’s stated quality-control threshold.
What the Published Data Does Not Show
Finnrick reports that approximately 8% of tested samples contained quantifiable endotoxin.
However, the published summary does not clearly state:
- How many samples exceeded 5 EU per vial
- How many exceeded 40 EU per vial
- How many were only marginally above the laboratory’s limit of quantification
- How many resulted in a formal batch rejection or other adverse quality determination
Because those figures are not separately reported, the approximately 8% quantifiable category should not automatically be interpreted as an 8% failure rate.
The published category appears to encompass samples with endotoxin concentrations above the laboratory’s quantification limit, which is a different analytical threshold from Finnrick’s stated 40 EU-per-vial quality-control limit.
The available information therefore does not allow a reader to calculate the actual percentage of samples that exceeded Finnrick’s stated specification.
Interpreting the Data in Context
Finnrick provides commercial laboratory testing services, including endotoxin analysis. Its article serves both an educational purpose and as information about an analytical service available to researchers.
That commercial context does not invalidate the underlying data, but it is still important to distinguish the reported analytical findings from conclusions that the published statistics do not directly establish.
The approximately 8% quantifiable result is useful information.
So is the corresponding observation that approximately 92% of the samples contained no quantifiable endotoxin.
Neither statistic, standing alone, establishes the actual percentage of samples that exceeded a defined quality-control specification.
For that determination, the individual results would need to be evaluated against the applicable specification.
What the Data Does Establish
Based on the published information, several conclusions can reasonably be drawn:
- Endotoxin can be detected in some peptide research materials.
- Trace or below-quantification assay responses were more common than quantifiable results.
- Approximately 8% of the tested samples contained quantifiable endotoxin.
- A quantifiable result does not automatically mean that a sample exceeded a defined quality-control specification.
- Approximately 92% of the samples contained no quantifiable endotoxin.
- The published summary does not disclose the percentage that exceeded Finnrick’s stated 40 EU-per-vial quality-control threshold.
- The published data is therefore insufficient to calculate a true above-specification or batch-failure rate.
Endotoxin analysis can nevertheless provide useful information when evaluating manufacturing cleanliness, water systems, equipment controls, handling practices, and batch-to-batch consistency.
The significance of any result should be interpreted according to the analytical method, applicable specification, and requirements of the research protocol.
Independent Testing Credit Program
Marsden Research Labs supports independent analytical testing and greater transparency through its Independent Testing Credit Program.
Eligible research customers may purchase a qualifying vial from an eligible Marsden Research Labs batch and independently submit that material to a qualifying analytical laboratory.
The participating researcher selects the laboratory independently. Testing is not restricted to Finnrick or to a laboratory selected by Marsden Research Labs.
For a qualifying request, the program may provide store credit for:
- The eligible laboratory testing expense, subject to the program’s current laboratory-credit limit
- The value of the qualifying vial submitted for independent testing
The laboratory report and supporting documentation are reviewed before store credit is approved.
Program requirements include verification of the originating Marsden Research Labs order, exact product and batch, qualifying analytical testing, laboratory documentation, and proof of the eligible laboratory expense.
Current program terms, limits, eligible testing categories, and submission requirements are maintained on the Independent Testing Credit Program page and should be reviewed before submitting material for testing.
This approach allows the program terms to remain centralized rather than relying on older articles that may contain outdated credit amounts or testing requirements.
Endotoxin Testing Is Only One Analytical Category
An endotoxin result addresses a specific analytical question. It does not establish every characteristic of a research material.
Depending on the material and research objective, additional analytical testing may include:
- Identity testing
- Purity analysis
- Peptide-content or quantity analysis
- Sterility or bioburden testing
- Heavy-metal analysis
- Residual-solvent testing
- Excipient identification
- Impurity characterization
- Stability testing
Each analytical method provides different information.
For example, a high-purity chromatographic result does not establish endotoxin content, while an endotoxin result does not independently establish peptide identity or quantity.
Analytical results should therefore be evaluated collectively and according to the requirements of the applicable research protocol.
The Bottom Line
Finnrick’s published data supports the conclusion that endotoxin is measurable in a minority of the peptide samples it evaluated.
It does not, based on the information published in the article, establish that approximately 8% of those samples failed Finnrick’s quality-control specification.
The distinction between detection, quantification, specification limits, and analytical suitability matters.
Marsden Research Labs supports independent laboratory verification so researchers can evaluate individual batches using the analytical methods and specifications relevant to their own laboratory work.
For laboratory research use only. Marsden Research Labs products are not intended for human or veterinary use, human consumption, diagnosis, treatment, prevention, or other clinical applications.